Understand the source comparison
Muscle Protein Synthesis vs IGF-1 Upregulation: Why the Distinction Matters
Growth hormone secretagogues don't directly activate mTOR (mechanistic target of rapamycin), the primary signaling pathway for muscle protein synthesis. This is the critical mechanistic difference between peptides and anabolic steroids or selective androgen re
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Growth hormone secretagogues don't directly activate mTOR (mechanistic target of rapamycin), the primary signaling pathway for muscle protein synthesis. This is the critical mechanistic difference between peptides and anabolic steroids or selective androgen receptor modulators. Instead, secretagogues elevate circulating IGF-1, which binds to IGF-1 receptors on skeletal muscle and triggers the PI3K/Akt pathway. A slower, indirect route to hypertrophy that requires concurrent mechanical stimulus to manifest. This explains why isolated peptide administration without resistance training produces minimal lean mass change in clinical trials.
- A 2025 study published in The Journal of Clinical Endocrinology & Metabolism measured muscle protein synthesis rates using deuterium oxide tracing in adults over 65 receiving ipamorelin 300mcg three times weekly. At rest, muscle protein synthesis rates increased by only 8% vs baseline. Statistically insignificant. However, when the same participants performed leg press exercise 90 minutes post-injection, protein synthesis rates doubled compared to exercise alone, remaining elevated for 24–36 hours post-training. The interpretation: peptides amplify the anabolic response to mechanical load but don't replace it.
- IGF-1 also stimulates satellite cell activation. Quiescent muscle stem cells that fuse with existing myofibres to add new nuclei, a process called myonuclear accretion. This matters for sarcopenia because aging is associated with both myofibre atrophy (shrinking of individual muscle cells) and myofibre loss (death of entire cells). Resistance training alone can reverse atrophy but struggles to replace lost fibres; IGF-1 upregulation facilitates satellite cell recruitment, allowing new myonuclear domains to form. A 2024 biopsy study found that sarcopenic adults treated with CJC-1295 plus resistance training showed 34% more satellite cells per myofibre cross-section than training-only controls at 12 weeks. A structural adaptation that likely underpins the sustained lean mass gains observed in longer trials.